Stepien O, Iouzalen L, Herembert T, Zhu D L, Marche P
Laboratory of Pharmacology, Université René Descartes and CNRS URA 1482, Faculté de Médecine Necker, Paris, France.
Int J Cardiol. 1997 Dec 31;62 Suppl 2:S79-84. doi: 10.1016/s0167-5273(97)00244-1.
In both atherosclerosis and arterial hypertension, structural and functional abnormalities result in vascular hypertrophy that is associated with an increased ratio of vascular media thickness to lumen diameter and hyperreactivity of vascular smooth muscle cells (VSMCs), resulting in uncontrolled cell migration and growth in vivo. In culture, VSMCs isolated from the spontaneously hypertensive rat (SHR) also display exaggerated growth and/or proliferation compared to VSMCs isolated from normotensive control Wistar Kyoto (WKY) rats. In vitro studies of cultured VSMCs can therefore be used as a model to investigate the mechanisms whereby a drug such as amlodipine can exert its antihypertensive and antiatherogenic effects. The present in vitro investigations examine the mechanisms whereby amlodipine reduces VSMC growth/proliferation promoted by basic fibroblast growth factor (bFGF), a peptide growth factor likely to participate in the vascular smooth muscle hypertrophy of the SHR. VSMCs from SHR and/or WKY rat aortae were isolated, passaged, and cultured. The influence of amlodipine on VSMC growth/proliferation was studied by measuring DNA synthesis and cell number under experimental conditions, which allowed us to determine the cell cycle phase in which amlodipine exerts its effects. Amlodipine was found to inhibit growth and bFGF-induced DNA synthesis in a concentration-dependent manner. Delayed addition of amlodipine showed that the drug exerts its effect early in the G1 phase, a result that was confirmed by the finding that amlodipine could not inhibit bFGF-induced DNA synthesis in VSMCs arrested at the G1/S boundary. In comparative experiments, the inhibitory effect of amlodipine on both cell growth and DNA synthesis was found to be of similar magnitude in SHR- and WKY-derived VSMCs. It is therefore likely that by modulating cell growth/proliferation induced by bFGF, amlodipine may reduce the vascular hypertrophy of the SHR. Since amlodipine also has been found to inhibit VSMC migration, one may reasonably envisage that these characteristics are important components of the antiatherogenic properties of the drug.
在动脉粥样硬化和动脉高血压中,结构和功能异常都会导致血管肥大,这与血管中膜厚度与管腔直径之比增加以及血管平滑肌细胞(VSMC)的高反应性相关,进而导致体内细胞不受控制地迁移和生长。在培养条件下,与从正常血压对照的Wistar Kyoto(WKY)大鼠分离的VSMC相比,从自发性高血压大鼠(SHR)分离的VSMC也表现出过度生长和/或增殖。因此,对培养的VSMC进行的体外研究可作为一种模型,用于研究氨氯地平这类药物发挥其抗高血压和抗动脉粥样硬化作用的机制。目前的体外研究探讨了氨氯地平降低碱性成纤维细胞生长因子(bFGF)促进的VSMC生长/增殖的机制,bFGF是一种可能参与SHR血管平滑肌肥大的肽生长因子。从SHR和/或WKY大鼠主动脉分离VSMC,传代并培养。通过在实验条件下测量DNA合成和细胞数量来研究氨氯地平对VSMC生长/增殖的影响,这使我们能够确定氨氯地平发挥作用的细胞周期阶段。发现氨氯地平以浓度依赖的方式抑制生长和bFGF诱导的DNA合成。延迟添加氨氯地平表明该药物在G1期早期发挥作用,这一结果得到了以下发现的证实:氨氯地平不能抑制停滞在G1/S边界的VSMC中bFGF诱导的DNA合成。在比较实验中,发现氨氯地平对SHR和WKY来源的VSMC的细胞生长和DNA合成的抑制作用程度相似。因此,氨氯地平可能通过调节bFGF诱导的细胞生长/增殖来减轻SHR的血管肥大。由于还发现氨氯地平可抑制VSMC迁移,人们可以合理地设想这些特性是该药物抗动脉粥样硬化特性的重要组成部分。